PMID- 25317248
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141015
LR  - 20211021
IS  - 1948-9358 (Print)
IS  - 1948-9358 (Electronic)
IS  - 1948-9358 (Linking)
VI  - 5
IP  - 5
DP  - 2014 Oct 15
TI  - HLA alleles may serve as a tool to discriminate atypical type 2 diabetic 
      patients.
PG  - 711-6
LID - 10.4239/wjd.v5.i5.711 [doi]
AB  - AIM: To investigate whether the presence of human leukocyte antigen (HLA) marker 
      could add new information to discriminated atypical diabetic type 2 patients. 
      METHODS: We analyzed 199 patients initially diagnosed as type 2 diabetes who are 
      treated in special care diabetes clinics (3(rd) level). This population was 
      classified in "atypical" (sample A) and "classic" (sample B) according to HLA 
      typing. We consider "classic patient" when has absence of type 1 diabetes 
      associated HLA alleles and no difficulties in their diagnosis and treatments. By 
      the other hand, we considered "atypical patient" when show type 1 diabetes 
      associated HLA alleles and difficulties in their diagnosis and treatments. The 
      standard protocol Asociacion Latinoamericana de Diabetes 2006 was used for 
      patients follow up. To analyze differences between both populations in 
      paraclinical parameters we used unpaired t tests and contingence tables. 
      Bivariate and multivariate analyses were carried out using the SPSS software 
      program. In all studies we assume differences statistically significant, with a 
      P-value < 0.05 corrected and 95%CI. RESULTS: The typing HLA in the "atypical" 
      populations show that 92.47% patients presented at list one type 1 diabetes 
      associated HLA alleles (DQB1*0201-0302 and DR 3-4) and 7.53% had two of its. The 
      results showed for categorical variables (family history, presence or absence of 
      hypertension and/or dyslipidemia, reason for initial consultation) the only 
      difference found was at dyslipidemia (OR = 0.45, 0.243 < OD < 0.822 (P < 0.001). 
      In relation to continuous variables we found significant differences between 
      atypical vs classic only in cholesterol (5.07 +/- 1.1 vs 5.56 +/- 1.5, P < 0.05), 
      high density lipoproteins (1.23 +/- 0.3 vs 1.33 +/- 0.3, P < 0.05) and low density 
      lipoproteins (2.86 +/- 0.9 vs 3.38 +/- 1.7, P < 0.01). None of the variables had 
      discriminating power when logistic regression was done. CONCLUSION: We propose an 
      algorithm including HLA genotyping as a tool to discriminate atypical patients, 
      complementing international treatment guidelines for complex patients.
FAU - Fernandez, Mariana
AU  - Fernandez M
AD  - Mariana Fernandez, Matias Fabregat, Gerardo Javiel, Adriana Mimbacas, 
      Biodiversity and Genetic Department, Instituto de Investigaciones Biologicas 
      Clemente Estable, Montevideo, CP 11600, Uruguay.
FAU - Fabregat, Matias
AU  - Fabregat M
AD  - Mariana Fernandez, Matias Fabregat, Gerardo Javiel, Adriana Mimbacas, 
      Biodiversity and Genetic Department, Instituto de Investigaciones Biologicas 
      Clemente Estable, Montevideo, CP 11600, Uruguay.
FAU - Javiel, Gerardo
AU  - Javiel G
AD  - Mariana Fernandez, Matias Fabregat, Gerardo Javiel, Adriana Mimbacas, 
      Biodiversity and Genetic Department, Instituto de Investigaciones Biologicas 
      Clemente Estable, Montevideo, CP 11600, Uruguay.
FAU - Mimbacas, Adriana
AU  - Mimbacas A
AD  - Mariana Fernandez, Matias Fabregat, Gerardo Javiel, Adriana Mimbacas, 
      Biodiversity and Genetic Department, Instituto de Investigaciones Biologicas 
      Clemente Estable, Montevideo, CP 11600, Uruguay.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Diabetes
JT  - World journal of diabetes
JID - 101547524
PMC - PMC4138594
OTO - NOTNLM
OT  - Atypical diabetes
OT  - Clinical algorithm
OT  - Immunity molecular marker
EDAT- 2014/10/16 06:00
MHDA- 2014/10/16 06:01
PMCR- 2014/10/15
CRDT- 2014/10/16 06:00
PHST- 2014/02/27 00:00 [received]
PHST- 2014/05/01 00:00 [revised]
PHST- 2014/07/18 00:00 [accepted]
PHST- 2014/10/16 06:00 [entrez]
PHST- 2014/10/16 06:00 [pubmed]
PHST- 2014/10/16 06:01 [medline]
PHST- 2014/10/15 00:00 [pmc-release]
AID - 10.4239/wjd.v5.i5.711 [doi]
PST - ppublish
SO  - World J Diabetes. 2014 Oct 15;5(5):711-6. doi: 10.4239/wjd.v5.i5.711.